Replies to post #68552 on Biotech Values

[DewDiligence]

MNTA – Addendum on Copaxone patents:

rkrw suggested on SI that Teva’s US Copaxone patents may be invalid on their face—whether or not MNTA/NVS can prevail on the inequitable conduct argument. This may well be true; however, the inequitable conduct argument, if supported by the facts, may provide an easier route to victory than showing that the patents in question are technically flawed. I presume that MNTA/Sandoz will press both arguments during the course of the ongoing litigation.